Leaflet MANINIL 3.5mg tablets


Indicated for: type 2 diabetes mellitus

Substance: glibenclamide (sulfonylurea antidiabetic)

ATC: A10BB01 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Sulfonylureas)

Glibenclamide is an antidiabetic medication from the sulfonylurea class, used to control blood sugar levels in patients with type 2 diabetes. It works by stimulating the pancreas to produce more insulin, thereby helping to lower blood sugar levels.

It is recommended as part of a treatment plan that includes a balanced diet, regular physical activity, and blood sugar monitoring. Glibenclamide is effective in reducing the risk of diabetes-related complications, such as damage to small blood vessels (retinopathy, nephropathy).

Side effects may include hypoglycemia (excessive drop in blood sugar), nausea, weight gain, dizziness, or allergic reactions. It is important for patients to follow the prescribed dosage and watch for signs of hypoglycemia, such as shaking, sweating, or confusion.

General data about MANINIL 3.5mg

  • Substance: glibenclamide
  • Date of last drug list: 01-08-2018
  • Commercial code: W07206003
  • Concentration: 3.5mg
  • Pharmaceutical form: tablets
  • Quantity: 120
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: BERLIN-CHEMIE AG - GERMANIA
  • Holder: BERLIN-CHEMIE AG (MENARINI GROUP) - GERMANIA
  • Number: 10006/2017/01
  • Shelf life: 3 years

Concentrations available for glibenclamide

  • 1.75mg
  • 3.5mg
  • 5mg